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Autophagy is considered to be the primary degradative pathway that takes place in all eukaryotic cells. Morphologically, the
autophagy pathway refers to a process by which cytoplasmic portions are delivered to double-membrane organelles, called
autophagosomes, to fuse with lysosomes for bulk degradation. Autophagy, as a prosurvival mechanism, can be stimulated by
different types of cellular stress such as nutrient deprivation, hypoxia, ROS, pH, DNA damage, or ER stress, promoting
adaptation of the cell to the changing and hostile environment. The functional relevance of autophagy in many diseases such as
cancer or neurodegenerative diseases remains controversial, preserving organelle function and detoxification and promoting cell
growth, although in other contexts, autophagy could suppress cell expansion. Poly(ADP-ribosyl)ation (PARylation) is a covalent
and reversible posttranslational modification (PTM) of proteins mediated by Poly(ADP-ribose) polymerases (PARPs) with
well-described functions in DNA repair, replication, genome integrity, cell cycle, and metabolism. Herein, we review the
current state of PARP1 activation and PARylation in starvation-induced autophagy.
1. Introduction
ADP-ribosylation is a posttranslational modification of
proteins with a prominent function in the regulation of
diverse biological processes such as, among others, chroma-
tin dynamics, gene transcription, and cell response to DNA
damage. Utilizing the oxidized form of NAD+ as a substrate,
Poly(ADP-ribose) polymerase (PARP) (17 members) cata-
lyzes the covalent attachment of ADP-ribose units onto
glutamate, aspartate, tyrosine, lysine, and serine residues of
target proteins [1]. Based on their enzymatic activity, PARP
enzymes are defined as either mono-ADP-ribose polymer-
ases because they add a single ADP-ribose unit onto their
targets (PARP3, vPARP, PARP6, tiPARP, PARP8,
PARP10, PARP11 PARP12, PARP14, and PARP15) or
Poly(ADP-)ribose polymerases when they create linear or
branched Poly(ADP-ribose) chains (PAR chains) (PARP1,
PARP2, PARP5a, and PARP5b). No enzymatic activity has
been identified for PARP13 while mono-ADP-ribosylation
of ubiquitin has been proposed for PARP9 in heterodimeri-
zation with the histone H3 ligase Dtx3L (see Table 1) [1, 2].
PARP1, the founding member of the family, has been
long defined as a central DNA damage-responsive element
required for the maintenance of genome integrity. In
response to DNA strand interruptions inflicted by various
genotoxic agents, PARP1 promotes an immediate and
local production of Poly(ADP-ribose) chains needed for
chromatin relaxation through the addition of negatively
charged ADP-ribose units onto histones and necessary to
coordinate the spatiotemporal assembly of PAR-binding
proteins including DNA repair proteins, transcription fac-
tors, DNA- and RNA-binding proteins, and intrinsically dis-
ordered proteins [3]. As fundamentally important as PAR
synthesis in stress response is the following degradation
of the ADP-ribose chains by families of ADP-ribose
hydrolases. While some enzymes preferentially degrade
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Table 1: Nomenclature, enzymatic activity, and biological functions of PARP proteins.
PARP Alternative names Demonstrated activity Cellular localization Biological processes
PARP1 ARTD1 PARylation (i) Nucleus
(i) DNA repair
(ii) Genome integrity
(iii) Transcription
(iv) Replication
(v) Cell cycle
(vi) Metabolism and development
(vii) Proteasome degradation
(viii) Diseases: cancer, inflammation, and HIV
PARP2 ARTD2 PARylation (i) Nucleus
(i) DNA repair
(ii) Genome integrity
(iii) Transcription
(iv) Cell cycle
(v) Metabolism
(vi) Cancer/inflammation
PARP3 ARTD3 MARylation (i) Nucleus
(i) DNA repair
(ii) Genome integrity
(iii) Cell cycle
(iv) Development
(v) Cancer
PARP4 ARTD4/VPARP MARylation
(i) Nucleus
(ii) Exosomes
(iii) Cell membrane
(i) Vault biology
(ii) Cancer
TNK1 ARTD5/PARP5A PARylation
(i) Nucleus
(ii) Telomeres
(iii) Golgi
(iv) Cytoplasm
(i) Mitotic spindle
(ii) Telomere maintenance
(iii) Metabolism
TNK2 ARTD6/PARP5B PARylation
(i) Nucleus
(ii) Telomeres
(iii) Golgi
(iv) Cytoplasm
(i) Inflammation
(ii) Telomere maintenance?
(iii) Metabolism
PARP6 ARTD17 Not determined (i) Cytoplasm? (i) Cell proliferation
PARP7 ARTD14/TIPARP MARylation
(i) Nucleus?
(ii) Cytoplasm?
(i) Transcription
(ii) Antiviral effects
(iii) Cytosolic RNA processing
PARP8 ARTD16 Not determined (i) Not determined (i) Unknown
PARP9 ARTD9/BAL1 Inactive/unknown
(i) Nucleus
(ii) Cell membrane
(iii) Cytoplasm?
(i) Cell migration
(ii) Tumor formation
PARP10 ARTD10 MARylation
(i) Nucleus
(ii) Cytoplasm
(i) Cell proliferation
(ii) Transcription
(iii) Cytosolic RNA processing
PARP11 ARTD11 Not determined (i) Unknown (i) Unknown
PARP12 ARTD12 MARylation (i) Cytoplasm (i) RNA processing
PARP13 ARTD13/ZAP/ZC3HAV1 Inactive/unknown (i) Cytoplasm (i) RNA processing
PARP14 ARTD8/BAL2 MARylation (i) Nucleus
(ii) Cell membrane
(i) Inflammation
(ii) Transcription
(iii) Metabolism
(iv) Tumor formation
(v) Nuclear RNA processing
PARP15 ARTD7/BAL3 MARylation (i) Cytoplasm
(i) Cytosolic RNA processing
(ii) Tumor formation
PARP16 ARTD15 MARylation (i) Cell membrane
(ii) ER
(i) Unfolded protein response (UPR)
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Poly(ADP-ribose) chains (the macrodomain containing
PARG endowed with exo- and endoglycohydrolase activities
or ARH3), the removal of the last protein ADP-ribose bond
is mediated by a panel of recently identified enzymes includ-
ing ARH3, TARG1, macroD1, macroD2, NUDT16, or
ENPP1 [4].
Owing to its decisive role in DNA repair, the inhibition of
PARP1 has emerged as a prominent therapeutic option in
cancer treatment, either to potentialize the cytotoxic action
of chemotherapy or radiation therapy or to target repair-
deficient tumors [5]. To date, three PARP inhibitors have
been FDA approved for the treatment of ovarian or breast
cancer, namely, Olaparib, Rucaparib, and Niraparib.
The last decades have helped to expand the knowledge on
other members of the PARP family and the number of func-
tions of PARP proteins in different cellular pathways. The
effects of PARP1 activation (considered the major producer
of Poly(ADP-ribose)), its autoPARylation, and PARylation
of different targets (which is called transPARylation or
heteroPARylation) are translated to cellular responses in
several different ways.
Although the majority of functions mediated or regulated
by PARPs are related to cellular stress response as DNA dam-
age, it is well known that recent investigations have increased
the number and importance of documented PARP-mediated
functions and PARylation in noncellular stress situations
(see Table 1). The great majority of PAR has a nuclear
localization where it will act as a potent posttranslational
modification of proteins related to maintenance of genome
integrity, gene expression, or cell cycle. However, the cyto-
plasm has been described, including various organelles, as a
large receptor of Poly(ADP-ribose) and single molecules
of ADP-ribose. Moreover, PARylated proteins can be
transferred to the cytosol, interfering in many different
biochemical processes [6]. Noncovalent binding of free
Poly(ADP-ribose) is considered a factor of high relevance
in the function of the targeted protein. In conclusion, the
consequences of PARylation, PAR signaling, or the biochem-
ical interaction of PARPmembers with partner proteins affect
many cellular events ranging from genome homeostasis to
vital cellular functions such as cell proliferation, differentia-
tion, metabolism, prosurvival pathways, and programmed
cell death.
For some years, it has also become increasingly appreci-
ated that PARP1-catalyzed Poly(ADP-ribosyl)ation regulates
cell survival and stress adaptation programs, with among
them, the well-conserved self-eating mechanism of cell
survival termed autophagy. Herein, we concentrate on the
most recent discoveries to encompass the different mecha-
nisms by which PARP1 activity operates in autophagy during
periods of nutrient deprivation.
2. PARP-Dependent Bioenergetic Changes:
NAD+ Catabolism and Downstream
PARP1 is considered the main guardian of the genome, able
to synthesize up to 85%-90% of the PAR polymer that is
needed to maintain cell homeostasis. While the contribution
of PARP2 could be considered up to 10%-15%, contribution
of other PARPs seems insignificant compared to the total
Poly(ADP-ribose) pool. Biochemically, PARP1 constitutes
the majority of NAD+ catabolic activity in the cells, depleting
NAD+ to 20% of its normal levels within minutes upon DNA
damages [7]. NAD+ provides a direct link between the cellu-
lar redox status and the control of signaling events, since it is
considered an oxidoreductase cofactor in cell physiology and
acts as a substrate for a wide range of enzymes. NAD+ could
be considered to be metabolic fuel in high competence for
three kinds of proteins: NAD+-dependent protein deacety-
lases or Sirtuins, Poly(ADP-ribose) polymerases, and tran-
scription factors. Depending on the metabolic context in
which the cell is located, the competition for NAD+ will be
unbalanced towards one pathway or another. Generally,
NAD+ requirement in the case of PARPs, mainly DNA-
dependent PARPs, is higher and is accompanied by a high
amount of ATP to complete the synthesis and PARylation of
various acceptors. Therefore, PARP overactivity will be trig-
gered in a situation of ATP depletion and promotes a scenario
that will compromise the cells. Glycolysis is probably themost
immediate energy pathway compromised during PARP over-
activation. NAD+ is an important cofactor in metabolism; the
reduction of NAD+ to NADH is essential for the glyceralde-
hyde 3-phosphate (GAPDH) step of glycolysis and multiple
steps in the tricarboxylic acid cycle (TCA). All those situations
that could compromise glycolysis immediately impair the
major source of ATP production in cells, used, for example,
in the cycle to regenerate NAD+, and the Krebs cycle. Since
the major source to create secondary metabolites and antiox-
idant precursors is blocked, this creates a negative feedback
loop that compromises cell survival [7, 8].
Inside the nucleus, we could focus on the high competence
for NAD+ in PARP1/SIRT1, cleaving NAD+ to produce nico-
tinamide and ADP-ribosyl products and the enzymes related
with Poly(ADP-ribose) recycling such as Poly(ADP-ribose)
glycohydrolases (PARGs) and ADP-ribose hydrolase 3
(ARH3). SIRT1 is a NAD+-dependent type III histone deace-
tylase member of the Sirtuin family. Sirtuin proteins catalyze
the reaction of NAD+ with acyl lysine groups to remove the
acyl modification from substrate proteins, resulting in the
final production of deacetylated lysine, nicotinamide, and
2′-O-acetyl-ADP-ribose (OAADPr). This deacetylation
integrates cellular NAD+ metabolism into a large spectrum
of cellular processes, such as cell metabolism, cell survival,
cell cycle, apoptosis, DNA repair, and mitochondrial
homeostasis [9, 10]. OAADPr is considered a second mes-
senger linked with decreased ROS-mediated stress, gene
silencing, and ion channel activation [10]. On the other hand,
several studies report that PARPs and Poly(ADP-ribosyl)a-
tion can modulate mitochondria from the nucleus through
PAR translocation, depletion of NAD+ pools, and epigenetic
regulation of nuclear genes that are involved in mitochon-
drial DNA transcription or repair. Short PAR chains and
single units of ADP-ribose (ADPr) can be produced from
the coordinate actions of PARPs and PARG, which cleavage
Poly(ADP-ribose) to free monomers of ADPr. Several data
suggest that PARP1-induced loss of ATP requires PARG
activity. Under specific scenarios of PARP1 hyperactivation,
PARG-dependent production of the single unit of ADPr
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can exit from the nucleus and interfere with ATP
production in mitochondria, promoting nonenzymatic
ADP-ribosylation of cell death proteins and metabolic
cofactors [4, 6, 7].
Free units of ADPr andOAADPr have potential signaling
functions in cytoplasm, suggesting mitochondrion-related
enzymes as putative targets. The existence of enzymes capa-
ble of metabolizing these second messengers suggests that
their cellular concentrations may be targeted in metabolism
in several pathophysiological situations such as neurodegen-
erative diseases, acute brain injury, or cancer [4, 6]. Many
enzymes target OADDPr and Poly(ADP-ribose) preventing
unnecessary effects in the nucleus and cytoplasm. OADDPr
is cleaved to ADPr by macroD1, macroD2, and ARH3
enzymes in the nucleus; moreover, in mitochondria, the
interconnected activity of PARG/ARH3 degrades short
Poy(ADP-ribose) chains to ADPr in the mitochondrial
matrix, preventing the heteroPARylation of AIF (apoptosis-
inducing factor), mitochondria collapse, and PARthanatos
cell death [8].
In the last 30 years, a superfamily of enzymes has gained
prominence in the field of Poly(ADP-ribosyl)ation and
PAR-mediated biology. These ADPr hydrolases, called
NUDIX hydrolases, are considered the major regulators
of the intracellular levels of ADPr. The NUDIX superfamily
is found in all classes of organisms among eukaryotes,
bacteria, and viruses [11]. NUDIX hydrolases are basically
pyrophosphohydrolases that act on substrates with the
general structure NDP-X (nucleoside diphosphate linked
to some moiety, X). Various cellular compounds include
the canonical structure NDP-X and also contain oxidized
and canonical nucleoside di- and triphosphates, nucleotide
sugars, and alcohol, presenting potential toxic properties;
so, originally, NUDIX enzymes were proposed to function
in housecleaning controlling the availability of intermediates
in metabolism [11]. NUDIX hydrolyze ADPr to adenosine
monophosphate (AMP) and ribose 5-phosphate in an
Mg2+-dependent reaction (or a similar cofactor, e.g., Zn2+),
thereby limiting free ADPr accumulation. In human cells,
members of the NUDIX family often exhibit substrate selec-
tivity for specific nucleotide derivatives; NUDT9, an ADPr
pyrophosphatase, is highly specific for the mitochondrial
ADPr pool, while NADT5, an ADP-sugar pyrophosphatase,
only has preference for cytosolic ADPr and other
ADP-sugar conjugates; both enzymes catalyze the produc-
tion of AMP [12, 13]. Recent studies have also demonstrated
that NUDIX are potential metabolizing enzymes of the
byproduct of Sirtuin activity, OADDPr, producing AMP
and O-acetylated-ribose-5-phosphate [11]. These studies
allowed describing an active crosstalk between mitochondrial
PARG/ARH3 Poly(ADP-ribose) metabolisms and subse-
quently altering the levels of GTP and ATP.
Mitochondrial AMP phosphorylation by adenylate
kinase 3 (AK3) and low NAD+ levels causes depletion in
mitochondrial GTP, compromising mitochondrial fusion.
On the other hand, high levels of AMP also increase
AMP :ADP ratios, which lead to the activation of AMPk
kinases. AMPk phosphorylates the mitochondrial fusion
factor or MFF inducing Drp1 translocation from cytosol to
mitochondria causing constriction and fission. The final situ-
ation results in excessively fragmented mitochondria and
eventually leads to mitophagy [14]. Additionally, better
understanding of mitochondrial profiles of Poly(ADP-
ribosyl)ation and mono(ADP-ribosyl)ation and the com-
plexities of AMPk in relation to mitochondrial dynamics
should be taken up in future studies. The crosstalk
between nuclear DNA-dependent NAD+, energy collapse
dependent of PARP1 overactivation, and AMPk activity in
response to the proautophagy stimulus will be analyzed in
other sections of this review.
PARP1 and SIRT1 compete for a limited nuclear pool of
NAD+, and of course, each activity could guide the other one,
leading to diverse consequences for cells. Different in vivo
studies have demonstrated the metabolic crosstalk in impor-
tant models of differentiation, neurogenesis, inflammation,
and cancer. PARP inhibitors increase intracellular NAD+
levels, promoting specific nuclear deacetylase activity of
SIRT1 but not affecting other SIRTs located in cytoplasm or
mitochondria; however, the negative correlation was only
found under physiological conditions in specific scenarios
such as muscle differentiation [15]. In the case of PARP2,
new data reflects no evident competence for NAD+ with
SIRT1 and shRNA-mediated depletion of PARP2 produces
little effect on NAD+ balance; however, there is a demon-
strated physical interaction between both proteins. Parp2−/−
mice exhibit elevated SIRT1 expression with decreased
acetylation of SIRT1 targets FOXO1 and PGC-1α which are
transcriptional regulators of mitochondrial bioenergetics
due to the fact that 63% of mitochondrial localized proteins
contain lysine acetylation sites [16]. Indeed, PARP2 deletion
in mice produces increased mitochondrial biogenesis in
upregulation genes involved in mitochondrial respiration,
antioxidant precursor activity, and lipid oxidation such as
tpn1, SDH, UCP2, or MCAD [16]. Thus, any consideration
of selective PARP2 inhibition in tumor cells and during met-
abolic unbalance will require better understanding of the
exact mechanism of PARP2-dependent metabolic regulation.
DNA-dependent PARPs can be considered transcrip-
tional modulators of several metabolic pathways. PARP1
and PARP2 could be considered important precursors of
the activity of different transcription factors that modulate
mitochondrial oxidative phosphorylation and lipid oxidation
such as PPARγ, FOXO1 by direct PARylation of them, and
their cofactors or modulators, consuming high amounts of
NAD+ and ATP [17]. However, the mechanism whereby
PARPs and PARylation transcriptionally mediate metabolic
transcription factors remains an unexplored field.
3. Cell Death Modulation by PARP1 during
Energy Stress
Over the course of the years, different groups have demon-
strated that the influence of PARP activity goes beyond the
nucleus and directly impacts NAD+ metabolism, energy
pathways, and oxidative metabolism. Many studies have
concluded that in a scenario of energy depletion guided by
oxidative stress, PARPs potentiate cell survival or cell death
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pathways [4, 18]. Reversible PARylation is a pleiotropic
regulator of various cellular functions, but uncontrolled
PARP activation may also lead to cell death. Moreover,
noncovalent PARylation or MARylation (PTM by mono-
mers of ADP-ribose) could be considered as an effective
cytosolic posttranslational modification of diverse MAPk
kinases and mitochondrial cell death factors, protecting cells
from acute DNA damage and stress conditions [18].
Attending the origin of DNA damages, the intensity and
“durability” of these damages, and the activation levels of
PARP1, we can define several destinations of the cells. When
DNA damage is minimal, the recruitment of PARP1 to sites
of DNA lesions activates the DNA damage response consum-
ing a controlled amount of NAD+ and ATP. Depending on
the type of lesion encountered, signaling mediated by mole-
cules such as p53 and ATM or ATR promote cell cycle arrest,
buying time for DNA repair enzymes to work [18, 19]. In this
context, the energy expenditure and NAD+ required can be
so great that the cells would enter almost immediately cell
death or cellular “suicidal” pathways mediated by PARyla-
tion because even though the DNA damage is repaired, the
collateral damage to the cellular energy machinery is too
great (see Figure 1).
To link PARP1 (potent consumer of ATP and NAD+)
energy collapse (oxidative phosphorylation to create ATP)
and oxidative stress (collapse of mitochondrial ETC), several
groups propose a theory in the form of a feedback loop: oxi-
dative conditions lead to DNA damage, triggering PARP1
overactivation that promotes more energy collapse by over-
PARylation and noncovalent MARylation that finally guide
the cells to die. The suicidal over-PARylation disrupts the
mitochondrial energy mechanisms, impairing the antioxi-
dant capacity of the Krebs cycle and favoring the liberation
of proapoptotic mitochondrial factors [20].
PAR-mediated cell death pathways can be subdivided
into two subcategories, depending on the Poly(ADP-ribose)
synthesis levels associated with the process (see Figure 1):
(1) Low PAR synthesis cell death: PARP1 and “suicidal”
proteases. Apoptosis is a nonreversible cell death pathway
characterized by activation of caspases, membrane depolari-
zation, exportation of mitochondrial death precursors, and
nuclear disintegration. Apoptosis involves a biochemical
expense which irreversibly leads to cell death. PARP1 is a
preferred substrate for several “suicidal” proteases (caspases,
calpains, cathepsins, granzymes, and matrix metalloprotein-
ases (MMPs)). The proteolytic action of these proteases on
PARP1 produces several specific cleavage fragments with dif-
ferent molecular weights. Each fragment could be associated
with specific stress situations inside the cells or cell death
programs [21]. When DNA damage is irreparable or the
signaling by PARP1 does not lead to an optimal repair,
cells enter irreversibly in cell death by apoptosis. In the
initial steps of apoptosis, caspases 3 and 7 cleave the
DNA-binding domain from the catalytic domain of PARP1
resulting in the inactivation of PARP1 and blocking the
ATP competition between PARPs and caspases [21]. (2)
Overactivation of PARP1 and cell death: PARthanatos
and necroptosis. In response to intense and sustained
damage, a large amount of Poly(ADP-ribose) is synthesized.
The overactivation of PARP1 collapses the cellular energetic
machinery and triggers necrosis, translated in proinflamma-
tory conditions in the tissues. An indeterminate amount of
Poly(ADP-ribose) could be exported to the cytosol and enter
the mitochondria, promoting PARylation on AIF proteins
(apoptosis-inducing factor). PARylated-AIF enzymes trans-
locate from the mitochondrion to the nucleus, triggering
chromatin condensation and DNA fragmentation into large
fragments (~50 kb) which irreversibly leads to cell death
called PARthanatos [22]. Actually, new studies have demon-
strated in DNA double-strand break-dependent energy
depletion models that the bioenergetic changes are adaptively
regulated during PARthanatos, especially under macroauto-
phagy deficiency [23].
For decades, necrosis has been considered a passive and
unregulated process, linked in many cases to overactivation
of PARP1 that leads the cell to a scenario of energy collapse,
oxidative chaos, and alteration of biomembranes. Current
studies have revealed several models of cell death with char-
acteristics of necrosis but are certainly regulated by various
proteins. A clear example is necroptosis mediated by RIP1
in response to TNFα death ligand released during inflamma-
tory conditions. Upon binding to TNFR1, TRADD, TRAFs,
RIP1, and cIAPs, proteins are recruited to form complex I
blocking apoptosis and leading to expression of proinflam-
matory cytokines. In this model, the overactivation of
PARP1 is considered a central element causing depletion of
NAD+/ATP, releasing cathepsins and favoring AIF translo-
cation. Furthermore, RIP1 protein has been proposed as a
clear acceptor of PAR chains. However, there are many
unanswered questions about whether necroptosis will be
considered or not such as a programmed cell death mecha-
nism [24, 25]. Autophagy is considered a housekeeping
mechanism to recycle long-lived protein, aberrant organelles,
and unfolded proteins and blocking intracellular pathogen
invasion. Autophagy is generally thought of as a survival
mechanism, although its deregulation has been linked to
nonapoptotic cell death. The goal of necroptosis is to elimi-
nate unnecessary or abnormal cells from the body under
stress situations, metabolic diseases, or other pathological
scenarios. Thus, a controlled recycling of damaged organelles
in response to energy deletion under PARP overcativation
palliate inflammatory response in tissues controlling the
levels of necroptosis and PARthanatos [25]. The idea of
autophagy as a mechanism for maintaining energy homeo-
stasis under a context of activation of PARP proteins will
be taken up in different sections of this review.
4. Autophagy in Mammalian Cells: Concept,
Types, and Functions
Macroautophagy (referred to simply as “autophagy”) is an
evolutionary ancient homeostatic “self-eating” pathway that
has been highly conserved among eukaryotic cells. Autoph-
agy is a catabolic lysosomal-associated process that targets
intracellular components, from small portions of the cytosol,
macromolecules, and unwanted organelles to chaperone-
associated cargoes. Morphologically, this pathway is charac-
terized by active membrane trafficking through formation
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of a unique double-membrane structure, called autophago-
some, where engulfed cytosolic structures are delivered to
the lysosome for bulk degradation [26, 27]. Autophagy plays
a housekeeping role in the turnover of long-lived proteins,
disposal of damaged organelles, and clearance of aggregate-
prone proteins. The main objective is the adaptation and
survival of the cell to the changing environment and finally
to maintain the normal growth cellular fate [28]. Considering
the origin of the subcellular material to be removed, we will
refer to “basal” autophagy, which describes a nonstop
removal of specific cargo, including unfolded or aggregated
proteins, lipid droplets, or whole organelles. Thus, macro-
autophagy is the most selective autophagy pathway and is
characterized by the formation of double-membrane intra-
cellular phagosomes. “Stress-induced autophagy” normally
is induced by nutrient deprivation or hypoxia and depends
on the availability of autophagomes; however, deprivation
of nutrients, oxygen, or growth factors does not exclude
the activation of selective autophagy towards a specific cel-
lular substrate with the ultimate goal of obtaining energy
and basic components (amino acids, nucleosides, or lipids)
used in cell maintenance and survival [29, 30].
Macroautophagy is interconnected with different path-
ways which regulate nutrient uptake, cell growth, and cell
Normal/weak PARP1 Cell survival
ApoptosisCaspases
No efficient PARylation
No DNA repair
PARP1Irreparable
i)
ii)
iii)
PARP1 activation (PAR)
DNA repair
UV light
lonizing radiation
Oncogene activation (ROS)
Aberrant metabolism
Mitos dysfunction
Antioxidant deficit
Replication errors
Chemicals/toxins
Alkylating agents
PARthanatos (AlF)PARP1
PARP1 AND+
ATP
Overactivation PARP1
PAR/MAR free
Necroptosis
(inflammation)
Autophagy
(adaptation)
Energy
collapse
Overactivation PARP1
PAR/MAR free?
Excessive
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↓
↓
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(ii)
(iii)
(iv)
(i)
(ii)
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Figure 1: The intensity of the stimulus that induces DNA damage and the degree of activation of PARP1 determines the fate of a cell toward
survival or death. Destination 1. When a slight damage occurs in DNA by endogenous or exogenous agents, PARP1 recognizes these damage
points; PARylates itself, histones, and structural chromatin-related proteins; and finally promotes recruitment of DNA repair enzymes. If the
DNA is repaired successfully, cells will survive. The effect on nuclear NAD+/ATP never leads to energy collapse. Destination 2. Multiple
intense damage that despite the activity of PARP1 never will be repaired successfully. The cell enters in irreversible apoptosis, effector
caspases 3 and 7 degrade PARP1 as the main competitor for the ATP, and the “eat-me” signal will appear on the cell surface. Destination 3.
Excessive DNA damages, though not necessarily lethal, produce a phenomenon of overactivation of PARP1 and over-PARylation in
nucleus. The energy consequences are lethal for cells, and the nuclear pool of NAD+/ATP will be seriously affected. Poly(ADP-ribose)
glycohydrolases and ADP-ribose hydrolases mediate a rapid turnover and recycling of the bulk of PAR modification on nuclear
PARylated proteins, autoPARylated PARPs, and free chains of ADP-ribose. The free monomers and little PAR chains are exported to
cytosol to induce mitochondrial AIF translocation to nucleus. Finally, cell will die in a non-caspase-dependent process or PARthanatos.
Overactivation of PARP1 consumes both NAD+ and ATP in nucleus triggering a high imbalance in the total pool of energy in the
cells. This total energy collapse alters the functions of the main energy organelles such as mitochondria, ribosomes, or endosomes,
favoring a total energy imbalance. At the same time, the presence of PAR chains and free ADP-ribose monomers in the cytosol modifies
enzymes such as RIP1, triggering necroptosis. As an alternative to death by necroptosis, autophagy appears as an adaptive pathway to try
to alleviate the energy crisis and prevent cell death arising. The nature of the stimulus and its durability will determine recycling of
damage organelles, misfolded proteins, or lipid aggregates. PARylation could be considered a highly dynamic posttranslational
modification of several proteins forming the autophagosome core or targeting intracellular components to be degraded. At the same time,
cells are given an alternative source of energy until the damage is repaired or the stress situation ceases.
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death programs. At the tissue level, autophagy should be
considered an active player in physiological processes
such as brain development, lineage differentiation, tissue
architecture, and regulation of energy homeostasis of
important organs (liver, brain, or heart).
It is widely demonstrated that extracellular proteins are
degraded in the lysosomes by phagocytosis, pinocytosis, or
endocytosis; however, intracellular unfolded or long-lived
proteins could be degraded and recycled into amino acids
by macroautophagy (proteins are engulfed in autophago-
somes and degraded after fusion with lysosomes), microauto-
phagy (soluble cytosolic proteins are directly internalized
through the membrane of the lysosomes), and chaperone-
mediated autophagy (CMA) (chaperone-dependent selection
of proteins that are then targeted to lysosomes and directly
translocated across the lysosome membrane for degradation)
to maintain ATP levels compatible with cell survival. Differ-
ent types of ordered organelle-selective autophagy pathways
have been described and characterized as new macroauto-
phagy examples, and in all of them, the active flux of
biomembranes to engulf portions of cytosol is the main mor-
phological characteristic. Many groups have described endo-
thelial reticulum or ER-phagy, mitophagy (mitochondria),
and ribophagy (ribosomes). Recent studies have determined
selective autophagosome formation, engulfing lipid droplets
(lipophagy) or toxic protein aggregates (aggrephagy) [28, 31].
The consequences of defects in autophagy for diseases are
apparent, with growing evidence linking the mutation or loss
of function of key autophagy genes to cancer, neuropathies,
heart disease, autoimmune diseases, and inflammation. In
cancer biology and tumor progression, it remains controver-
sial when considering autophagy as beneficial or harmful for
tumor cells and consequently for the growth and expansion
of the tumor. Autophagy may act as a tumor-suppressive
pathway, promoting cell cycle arrest or limiting necrosis
and inflammation, or as a prooncogenic pathway, favoring
cell survival in the presence of stressful conditions [29, 32].
The impact that autophagy causes in growth, development,
and expansion of a tumor can be summarized as follows:
tumor-initiating events (oncogene activation, impaired
DNA repair pathways, or high metabolic defaults) promote
cell proliferation, but also apoptosis, which limits tumor
growth. Tumor growth is initially limited by the absence of
a blood supply which can trigger autophagy-mediated
survival in the most metabolically stressed tumor regions,
commonly the hypoxic and starved center [33]. The eventual
recruitment of a blood supply prevents hypoxia, provides
glucose and amino acids, and reduces metabolic stress. In
tumors enriched by cells with defects in both apoptosis and
autophagy, necrotic cell death is stimulated in metabolically
stressed tumor regions and this necrosis is associated with
the activation of an inflammatory response, DNA damage,
and tumor progression. Thus, autophagy will play a dual role,
promoting survival, and adaptation to try to survive or in the
opposite case could be used as a “Trojan Horse” of these can-
cer cells, inhibiting angiogenesis, promoting more selective
apoptosis, and favoring the “eat-me” signals [33].
In other diseases such as neuropathies (Huntington’s,
Alzheimer’s, and Parkinson’s diseases) and ischemic heart
disease, autophagy is more widely accepted as beneficial
given its role in eliminating toxins, aberrant structures, and
promoting cell viability. Most neurodegenerative disorders
are characterized by the accumulation of misfolded proteins
that coalesce into “inclusions” and become visible under the
light microscope in the brains and spinal cords of affected
patients. The high sensitivity of mature neurons to misfolded
protein stress is well known, impairing the right neuronal
functions, promoting neuron cell death and neurodegenera-
tive disorders. In vivo animal models of neuropathies have
demonstrated that basal levels of autophagy are required
for the continued health and normal function of neurons
[34, 35]. Autophagy plays a key role in cardiomyocyte growth
and satisfactory heart activity. Autophagy may antagonize
ventricular hypertrophy by increasing protein degradation,
which decreases tissue mass in ischemic mouse models.
However, the rate of protective autophagy declines with
age, demonstrating an eventual autophagy/aging crosstalk.
5. Molecular Machinery of
Autophagosome Formation
In mammalian cells, autophagy sequestration features
important membrane traffic and begins with the active for-
mation of omegasome structures on the rough endoplasmic
reticulum called phagophores. Phagophores expand into
double-membrane autophagosomes while surrounding a
portion of the cytoplasm. Autophagosomes may fuse with
endosomes (product of endocytosis from the external micro-
environment) considering itself heterophagy (the cell is able
to internalize and degrade the material that originates from
outside of the cell). The newborn organelles are called amphi-
somes. The final destination of autophagosomes or amphi-
somes is to fuse with several lysosomes, which supply acid
hydrolases. In this new cellular compartment or autolyso-
some, the engulfed cargo will be recycled into macromole-
cules which are released in the cytosol (see Figure 2(a)).
One of the elusive fields of autophagy is deciphering the
molecular details of autophagosome biogenesis. In many
cases, the sequestration step is the most complex part of
autophagy because the cytoplasm must be segregated, often
in a direct or specific manner, and moved from the intracel-
lular space into the vacuole or lysosome lumen. Initiation of
double-membrane phagophores requires a specific cascade of
proteins, kinases, and E-like ligases to allow the recruitment,
formation, and sequestration of intracellular portions.
The journey into the molecular realm of autophagy began
with the identification of a set of evolutionary conserved
genes termed autophagy- (ATG-) related genes. Independent
genetic screens in yeast model systems have identified 38
ATG genes which are involved in various subtypes of
macroautophagy, including starvation-induced autophagy,
the cytoplasm-to-vacuole targeting (Cvt) pathway, and
pexophagy. Many of the genes have known orthologues in
other eukaryotes [36, 37].
In yeast, approximately 20 Atg proteins are considered
essential in the initial steps of phagophore formation and
closuring of autophagosomes. These proteins have been clas-
sified into five functional groups based on identified protein-
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Figure 2: Autophagy steps. (a) Membrane traffic associated to autophagosome formation. During autophagy, sequestration begins with the
formation of a phagophore that expands into a double-membrane autophagosome. (1) Stages of nucleation and elongation: the autophagic
charge will be engulfed by a double-lipid membrane called phagophore; the phagophore suffers elongation and closure to form an
autophagosome. (2) This autophagosome may, or not, fuse with an endosome to form an amphisome. (3) Finally, the amphisome will fuse
with lysosomes to form an autolysosome; in this step, acid hydrolases degrade the content of the autolysosome. Finally, the content may
be recycled through permeases that efflux the content to the cytosol. (b) Vesicle induction and phagosome creation. In response to stress
signals (starvation, hypoxia, and growth factor depletion), AMPk is activated and mTORC1 is inhibited, leading the stimulation of the
ULK1 core (activation). ULK1 kinase will phosphorylate Beclin-1 leading to VPS34 activation and the initiation of phagophore formation
(nucleation). ATG5-ATG12 conjugation involves ATG7 and ATG10 promoting an “E-like ligase” reaction of ATG12-ATG5-ATG16L
influencing on the phospholipidic elongation of the double membranes. The complex ATG12-ATG5-ATG16L acts like an E3-function
towards the LC3-PE assembly (LC3-II isoform) (elongation). Autophagosome maturations also involve fusion with lysosomes,
degradation and recycling of nutrients and metabolites, and recycling of LC3-I isoform. This membrane trafficking maintains the same
molecular events in nonselective and organelle-specific autophagy (mitophagy, ribophagy, and selective formation of amphisomes).
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protein interaction: Atg1 kinase complex, autophagy-specific
class III phosphatidylinositol 3-kinase or PI(3)K complex,
Atg9-Atg2/Atg18 complex, Atg12 conjugation complex,
and Atg8 conjugation system. Extensive research has demon-
strated functional interactions between them in the core of
newborn autophagosomes [38]. In mammalian cells, the
number is higher, including an intricate number of 400mem-
bers from different families. Classically, an integrated view of
mammalian autophagy establishes several steps in the final
double-membrane vesicle formation and engulfment of the
cargo [39, 40]. In this review, we focus on the phagophore
formation step, briefly describing the discovery and functions
of the key players sensing stress situations and promoting the
biochemical organization of double-membrane engulfing
proteins, organelles, or portions of the cytosol. The implica-
tion of the PARylation process in the regulation of the initial
stages of autophagy is analyzed in detail below.
6. Vesicle Induction: Phagophore
Formation—Regulation by AMPk
and mTORC1
Autophagy disassembles unnecessary or dysfunctional com-
ponents, resulting in a highly modulated catabolic pathway
in response to several physiological cell stresses and patho-
logical situations. The delicate balance between external
energy and nutrient supply and internal production and con-
sumption is a demanding task in the cells. There are two
interconnected proteins with the autophagy core-regulating
signaling network: AMPk and mTORC1. Both proteins
have the capacity to sense ATP and nutrient availability,
modulating the activity of the main ATG1 functional
orthologue in autophagosome closuring, called ULK1
(unc-51-like autophagy-activating kinase 1), in mammals.
AMP-activated protein kinase (AMPk) is a highly con-
served kinase considered to be the major energy sensor in
eukaryotic cells (sensing increases in intracellular AMP/ATP
and ADP/ATP ratios). AMPk is a serine/threonine kinase
that negatively regulates several enzymes of the lipid metab-
olism and activates different catabolic processes in eukaryotic
cells such as glucose uptake and metabolism, increasing ATP
generation pathways and decreasing ATP consumption
pathways. The balance of ATP synthesis/consumption allows
the maintenance of energy homeostasis, makes the energy
distribution into growth fates adequate, and triggers several
adaptive cellular programs during stressful situations. Struc-
turally, AMPk is a trimeric protein which presents three
differentiated domains: a catalytic subunit (α) and two regu-
latory subunits (β and γ). Different groups have determined
the crystal structure of several holoenzymes of AMPk
[41, 42]. The α subunit is encoded by two isoforms, while
the regulatory subunits present three isoforms in which
expression and combination into the AMPk structure are
dependent on the cell type. The most widely expressed
isoforms of AMPk are AMPkα1, AMPkβ1, and AMPkγ1;
however, other isoforms are more restricted to specific
tissues [42]. Under nutrient deprivation, hypoxia, DNA
damage, or mitochondrial failure, the AMP/ADP :ATP
ratio is sensed by LKB1 (liver kinase B1) which promotes
the regulatory phosphorylation of Thr172 on the AMPkα
subunit. Under this context, AMPk triggers catabolic pro-
cesses in order to restore the ATP levels through the
breakdown of different macromolecules [41, 42].
The mammalian target of Rapamycin (mTOR) is the
major nutrient sensor and a central regulator of growth and
metabolism in the cell, involved with processes including
angiogenesis, autophagy, and protein metabolism. mTOR is
a ubiquitously conserved serine/threonine kinase which rep-
resents the molecular core component of two multisubunit
complexes, mTORC1 and mTORC2. mTORC1 senses the
availability of amino acids, oxygen, and growth factors in
basal and stressed conditions, promoting cell growth and
anabolic pathways. On the other hand, mTORC2 is con-
sidered mainly as a regulator of the organization and rear-
rangement of the cytoskeleton [43]. Structural differences
between mTORC1 and mTORC2 determine the sensitivity
to Rapamycin. mTORC1 basically is formed by three
subunits, mTOR kinase (the functional unit), RAPTOR
(a regulatory protein sensitive to inhibition by Rapamycin),
and mLST8 (mammalian lethal with Sec13 protein 8). The
biochemical regulation of the mTORC1 activity is highly
dependent on the tumor suppressor TSC2, an upstream com-
ponent of the mTORC1 complex. TSC2 contains a GTPase
domain that inactivates the small Ras-like GTPase Rheb,
which has been shown to associate and activate the mTORC1
complex. Loss of TSC2 (and TSC1) leads to overactivation of
mTORC1, triggering translation (by p70S6k and 4E-BP1 regu-
lation), cell cycle, and cell growth (see Figure 2(b)). mTORC2
exhibits themTORkinase andmLTS8 subunits and alsoDEP-
TOR (DEP domain-containing mTOR-interacting protein),
and in this complex, RAPTOR is replaced by RICTOR
(Rapamycin insensitive companion of mTOR) which is
not sensitive to Rapamycin. Under energy and growth fac-
tor availability, mTORC2 controls cellular metabolism and
cytoskeleton dynamics (by Akt/GSk3β activation).
In terms of autophagy regulation, AMPk is considered
the major positive regulator of autophagy (catabolism) while
mTORC1 is considered the major negative regulator of
phagophore induction (anabolism). Under a proautophagic
scenario in the cells such as amino acid starvation or energy
depletion, binding of AMP or ADP to the γ subunit of AMPk
promotes Thr172 phosphorylation by LKB1 in the α subunit
and full activation of AMPk kinase. Recent studies suggest
that AMPk may also be a redox-sensing protein. Reactive
oxygen species (ROS) are naturally produced by many meta-
bolic reactions, notably by the production of ATP in the
mitochondria, and the strict control of their levels is impor-
tant for cellular homeostasis. ROS can indirectly activate
AMPk through increases in AMP or by post translational
modifications of the α subunit of AMPk [44]. AMPk
potently promotes autophagy inhibiting mTORC1 through
phosphorylation of TSC2 and indirectly blocks GTPase
Rheb-positive regulation on mTOC1 activity. In this context,
protein synthesis and several anabolic pathways are inhib-
ited; in a second step, AMPk binds the inactive autophagy
core ULK1 complex (formed by ULK1 kinase, ATG13 regu-
lator, ATG101/FIP200 which is a key component of the
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autophagy initiation process) and it phosphorylates the
component ULK1/2 kinase. As a consequence of a cascade
of autophosphorylations between ULK1/2 and ATG101/-
FIP200, ULK1 stimulates autophagy initiation.
The ULK1/2 complex translocates to the phagophore
localization, where it activates the class III phos-
phatidylinositol 3-kinase (class III PI3k) complex composed
of VPS34 (vacuolar protein sorting 34 or PI3k enzyme),
Beclin-1, VPS15, and ATG14 proteins. The kinase activity
of ULK1/2 enhances the VPS34 activity by direct phosphor-
ylation on Beclin-1. Class III PI3k activity is inhibited when
Beclin-1 is bound to Bcl-2 [45] but is stimulated upon
UVRAG recruitment to the complex [46]. Interestingly,
Ambra1 also directly binds Beclin-1 to regulate the stability
of Beclin-1/PI3k complex formation, competing under
specific proautophagic condition with Ambra1 to stabilize
the complex [46]. These events lead to autophagosome for-
mation following the extension and closure of the mature
autophagosomes (see Figure 2(b)). AMPk presumably sup-
presses nonessential vesicle trafficking in favor of membrane
trafficking into the autophagy pathway during nutrient
starvation in a VPS15/VPS34 class III phosphatidylinositol
3-kinase or PI (3) kinase-dependent manner [42, 47].
Following the nucleation step, other Atg proteins are
recruited to the membrane of the preautophagosomes to
promote the elongation and expansion of these newborn
organelles. Elongation membranes require Atg3, Atg4,
Atg7, Atg10, and an Atg5-Atg12-Atg16L complex to conju-
gate phosphatidylethanolamine (PE) to the microtubule-
associated protein 1 light chain 3- (LC3-) I to form LC3-II
[48]. The lipidated isoform LC3-II translocates from cyto-
plasm to the membrane of the preautophagosomes. Once
the autophagosomes are closed, engulfing organelles, pro-
teins, lipid droplets, or pathogens, a large majority of Atg
proteins are released from the surface of autophagosomes
to begin a new round of nucleation and membrane elon-
gation. Currently, there is controversy about the amount
of isoform LC3-II that is released and recycled from
mature autophagosomes, given that a percentage of LC3-II
is exposed on the inner side of the membranes and there-
fore would be subject to the action of lysosomal acid
hydrolases [49].
7. DNA Damage Response and Autophagy: A
Survival Association
In response to DNA damage induced by ROS (or reactive
nitrogen species (RNS)), cells activate a high number of path-
ways in order to repair and maintain genome integrity and
mediate survival pathways. Several kinds of proteins are
implicated in DNA damage responses (DDRs) which are
considered sensors (recognize and signal the damage),
mediators, and effectors (repair the damage). Mediators and
effectors are molecules that transduce nuclear signals to the
cytosol where several processes are activated in order to
better face adverse conditions. During DDRs, two events
must be controlled in order to promote adaptation and
survival: cell cycle checkpoints are activated to block pro-
liferation and allow repair, and cell death pathways must
be “kept on alert” in case of any unrepaired or excessive
DNA damage.
ROS have been repeatedly reported as early inducers of
autophagy due to their ability to produce oxidation of pro-
teins, alteration of biological membranes, and DNA damage.
The DNA lesions induced by ROS are involved in mutations,
cancer, and many other diseases. PARPs are pivotal
guardians in maintaining the integrity of the genome and
triggering diverse kinds of metabolic strategies to escape
from these adverse conditions. Currently, there are several
groups that have demonstrated an active connection between
the events that lead to DNA repair and the induction of
autophagy. Accumulating evidence suggests that autophagy
can be activated by DNA damage. ATM, a DNA damage-
activated kinase, has been described as an important link
between the DNA damage response (DDR) and the induction
of autophagy. ATM binds to double-strand breaks (DSBs)
in conjunction with the MRN complex and undergoes
autophosphorylation and activation. In turn, ATM activates
various downstream effector proteins, including Chk2 and
Chk1 involved in cell cycle control or the tumor suppressor
p53 which regulates cell survival versus death and HDAC1
and HDAC2 which are responsible for chromatin remodel-
ing [50]. In response to DNA damage by mitochondrial
ROS, external toxins, or irradiation, ATM is autophosphory-
lated within a MRN multiprotein complex that binds DSBs.
Activated ATM initiates a pathway that results in activation
of AMPk and its target TSC2 which functions as an inhibitor
of mTORC1, promoting ULK1-dependent autophagosome
formation. In addition, ATM directly phosphorylates and
stabilizes p53 which transcriptionally regulates various regu-
lators of the autophagic pathway including AMPk (energy
sensor and autophagy activator) in colon cancer cells and
during spermatogenesis, DAPK1 (death-associated protein
kinase 1 or regulator of cell death and autophagy), and PTEN
(phosphatase and tumor suppressor) in hepatocarcinoma
cells and other cancer cell lines [51–53].
Recent studies have shown that treatment of certain types
of tumor cells with genotoxic agents activate AMPk in a
nucleus-independent way. Etoposide activates specifically
the isoform AMPkα1 and not the α2 isoform, primarily
within nucleus. AMPkα1 activation is independent of ATM
signaling during etoposide-dependent DDRs. In this model,
etoposide increased the intracellular Ca+2 levels and leads
the activation of CaMkk2 kinase. AMPkα1 protected tumor
cells against etoposide by limiting entry into the S-phase
[54]. Considering the high energy cost and NAD+ involved
during nuclear overactivation of PARP1 in response to
DNA damage, regardless of whether the stimulus has a
proautophagic character or not, we must explain that in most
DDR models and autophagy described in normal and
tumor cells, the activation of PARP1 has triggered a
highly regulated process of autophagy aimed at survival.
Therefore, it is obvious to think that treatment combined
with PARP inhibitors inside a context of compromised
autophagy could be considered as an interesting and novel
antitumor therapy.
Several studies propose a role of PARP1 in the regulation
of autophagy in response to DNA damage. Different models
10 Oxidative Medicine and Cellular Longevity
of MEF 3T3 KO for PARP1 and in combination with PARP
inhibitors (PARPi) (PJ34, DPQ, or Olaparib) were used by
different groups to describe controlled overactivation of
PARP1 and highly modulated prosurvival autophagy in
response to alkylating and intercalating agents or ionizing
radiation. Doxorubicin treatment leads to overactivation of
PARP1, followed by ATP and NAD+ depletion that trigger
the nontoxic accumulation of autophagosomes in a model
of MEF parp1+/+ cells. An effective KO model for PARP1
(MEF parp1−/−) or the treatment of MEF parp1+/+ with
PARPi increased the sensitivity of the cells to Doxorubicin,
promoting high and uncontrolled levels of cell death. On
the other hand, pharmacological or genetic inhibition of
autophagy in a PARP1 KO model resulted in increased
necrosis, suggesting a PARP1-mediated protective role of
autophagy in response to chemotherapy [55]. A study in
Bax−/− Bak−/− double knockout MEFs has elucidated the sig-
naling pathway and biological function of autophagy induced
by MNNG, a commonly used DNA-alkylating agent. In
response to MNNG, double KO MEFs activated PARP1,
reducing intracellular ATP levels and triggering the AMPk
pathway and mTORC1 suppression. As a result, there was
an accumulation of autophagosomes and cells showed
Poly(ADP-ribose) profiles and persistent resistance for a long
time of treatment. Suppression of the AMPk pathway
blocked MNNG-induced autophagy and enhanced cell death
[56]. Finally, other studies obtained the same conclusions in a
nasopharyngeal carcinoma model exploring overactivation
of PARP1, PARylation-dependent energy depletion and
upregulation of the AMPk and ULK1 pathways in CNE-2
carcinoma cells upon ionizing radiation [57].
Many genotoxic agents activate AMPk kinase. Depend-
ing on the type of agent that induces DNA damage, the
downstream cell response mediated by AMPk will be differ-
ent. In tumor biology, the DNA-dependent AMPk activation
could be considered protumorigenic promoting cell viabili-
ty/survival or antitumorigenic cells would be more vulnera-
ble to genotoxic stress. All these studies have demonstrated
that autophagy should be considered as an important target
in cancer during the induction of DNA damage, and conse-
quently, new strategies based on the concept of synthetic
lethality of PARPi must be explored.
8. ROS-Induced DNA Damage Leads to
PARP1-Mediated AMPk Activation during
Starvation-Induced Autophagy
Cancer cells require a continuous source of nutrients and
oxygen, which is supplied through the growth of new blood
vessels, providing the tumor with nutrients and evacuating
metabolic wastes. At the cellular level, the exchange of nutri-
ents, oxygen, and growth factors with the intracellular
medium is a crucial process given that the absence of nutri-
ents (starvation) or the deficiency of oxygen (hypoxia) can
induce metabolic stress, oxidation of biomolecules, DNA
damage, and PARP1 activation, situations in which cells
activate autophagy as an adaptation and survival pathway.
In this context, one initial signal during starvation-induced
autophagy involves the activation PARP1 and the posttransla-
tional modification by Poly(ADP-ribosyl)ation of several
autophagy machinery proteins, favoring the autophagosome
closure.
A large amount of evidence has demonstrated that
starvation-induced autophagy is delayed in the absence of
PARP1 in different models of normal and tumoral cells.
Chemical inhibitors of autophagy as 3-methyl adenine
(3-MA) (inhibitor of class III PI3k) or siRNA-based knock-
down of ATG7 (nucleation of autophagosomes) completely
prevented autophagy in parp1−/− 3T3 MEFs under starvation
conditions. These data demonstrated that the absence of
PARP1 synergizes with 3-MA or genetic knockdown to
suppress autophagy during starvation. On the other hand,
chemical inhibition of Poly(ADP-ribosyl)ation with sev-
eral PARPi or specific silencing by siRNA of PARP1
reduced the percentage of parp1+/+ 3T3 MEFs showing
impaired membrane trafficking and LC3 translocation
during autophagosome formation. The importance of
controlled Poly(ADP-ribose) accumulation, due to PARP1
overactivation, in the initial steps of starvation-induced
autophagy has been demonstrated [58]. Concomitant elimi-
nation of Poly(ADP-ribose) glycohydrolase (PARG) (enzyme
degrading Poly(ADP-ribose) and ATG proteins1 (as ATG7,
ULK1, or ATG5) has demonstrated that PAR accumulation
after nutrient deprivation does not compromise cell viabil-
ity; thus, the increased levels of autophagy are not ascribed
to a cellular attempt to detoxify the excess of the PAR
polymer in autophagosomes. There may be a mechanism
of fine-tuning in the induction of PARylation-mediated
autophagy [58, 59].
The origin of PARP1 activation during starvation focuses
on the mitochondrial production and nuclear translocation
of ROS. Under these oxidative conditions, DNA damage is
recognized by PARP1, leading to PAR synthesis and trigger-
ing the initiation of autophagy. Although PARP1 knockout
cells also produce ROS during starvation, this production
does not lead tomassive DNA damage and PARP1 activation.
Consequently, these cells display an impaired starvation-
induced autophagy [58] (see Figure 3(a)).
How is PARP1 able to modulate the cytosolic assembly of
autophagosomes? Most classical studies have characterized
DNA-dependent PARPs as genome integrity maintenance
enzymes enclosing their activity in the nucleus and highly
fixed in DNA functions. However, different groups are dem-
onstrating that the influence of PARP activity goes beyond
the nucleus and directly impacts the main cellular metabolic
pathways, anabolism and catabolism. In general, PARPs
modulate NAD+ metabolism, energy pathways, and oxida-
tive metabolism so we could conclude that inside a scenario
of energy depletion guided by oxidative stress, PARPs poten-
tiate cell scape or cell death pathways. Reversible PARylation
is a pleiotropic regulator of various cellular functions but
uncontrolled PARP activation may also lead to cell death.
Moreover, noncovalent PARylation or MARylation could
be considered as an effective cytosolic posttranslational
modification of diverse MAPk kinases and mitochondrial cell
death factors. To link PARP1 (potent consumer of ATP and
NAD+) energy collapse (oxidative phosphorylation to create
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ATP) and oxidative stress (collapse of mitochondrial ETC),
several groups propose a theory in the form of a feedback
loop: oxidative conditions lead to DNA damage and trigger
PARP1 overactivation that intensifies energy collapse by
over-PARylation that finally guides the cells to die. The sui-
cidal over-PARylation disrupts mitochondrial energy mecha-
nisms, impairing the antioxidant capacity of the Krebs cycle
and favoring the liberation of proapoptotic mitochondrial
factors [20]. Autophagy must be considered a scape pathway
restoring ATP levels and blocking or delaying cell death.
DNA damage derived from starvation-induced ROS
triggers an important depletion in intracellular ATP levels
by overactivation of PARP1. The role of PARP1 in
starvation-induced autophagy is related to its ability to sense
DNA damage and deplete energy stores after its overactiva-
tion. This energy collapse is sensed by LKB1, promoting
AMPk activation and mTORC1 inhibition. Knockout cells
or cells with inefficient PARP1 activity show a potent
downregulation on specific phospho-Thr172 AMPkα by
LKB1. In consequence, the mTORC1 targets p70S6k and
4E-BP1 maintain their phosphorylation inhibiting autop-
hagosome formation [58]. However, in this model, it is
not possible to exclude the possibility of a perturbation
in Ca2+/calcium-/calmodulin-dependent kinase kinase 2
(CaMKK2) flux after PARP1 ablation upstream of the
mitochondria leading to altered ATP synthesis and AMPk
activation [60].
A nuclear population of the α isoform of AMPk has been
described to interact with PARP1 [35]. The modification of
AMPkα by Poly(ADP-ribose) and the mutual interaction
between PARP1 and AMPkα function as a multifaceted
molecular switch to optimize the initiation of autophagy. In
Figure 3, we summarize two demonstrated scenarios: (I)
starvation in a PARP1 activation context: a well-defined,
non-PARylated AMPkα population has been described in
the nucleus in functional interaction with PARP1 in
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Figure 3: (a) PARylation regulates autophagy through AMPKα activation. PARP1 forms a complex with AMPKα in nucleus (1). During the
starvation-induced autophagy, ROS production induces DNA damage and overactivation of PARP1. Auto-PARylated PARP1 is able to
modify by PARylation in the AMPKα1 subunit (2). The complex is disrupted and PAR-AMPKα is exported to cytosol (3). The presence
of PAR-AMPK and the continuous absence of amino acids and ATP depletion favor total activation of AMPKα population by LKB1,
inhibition of mTORC1, interaction PAR-phospho-AMPK/ULK1, and autophagosome formation (4). LKB1 activity is presumably
modified in a PARylation-dependent manner. (b) Starvation-induced ROS production was abrogated during the treatment with PARP
inhibitors. Following AMPKα1/PARP1 interaction (1), the AMPKα1 subunit is not PARylated and the nuclear export of AMPK is
inhibited (2 and 3). In spite of nutrient and energy depletion, AMPKα is inhibited; mTORC1 is partially activated and interacts with
ULK1 favoring its inhibition (4). Finally, the autophagosomes production will be delayed.
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nonstarved cells. During nutrient deprivation, ROS exported
from mitochondria induce DNA damage and PARP1 recog-
nizes this damage; in order to promote DNA repair, PARP1
is over activated, consuming ATP and NAD+ as substrates
to synthetize Poly(ADP-ribose). The energy depletion could
be sensed by LKB1 kinases to initiate autophagosome forma-
tion. PARylation of AMPkα at the AMPkα/PARP1 complex
is a key event in initiating autophagy. AMPkα is transiently
PARylated, disrupting the complex with PARP1 and being
exported from the nucleus to the cytosol. PARylated cytosolic
AMPkα triggers the total activation by LKB1 of the cytosolic
AMPkα pool. Finally, the total pool of active AMPkα inhibits
the mTORC1 complex and activates the autophagy core
ULK1 complex, favoring the nucleation and elongation of
phagophores around cytosol portions in order to be degraded
and recycled into amino acids and other essential biomole-
cules (see Figure 3(a)).
The specific Poly(ADP-ribosyl)ation of the α subunit is
needed to undergo AMPkα nuclear export. Abolishing the
active nuclear translocation of PARylated AMPkα or the
genetically engineered mutation on putative PARyaltion sites
blocks efficiently the nuclear export compromising the
autophagosomes formation [59]. The interaction between
PARP1 and AMPkα has been described for DNA damage-
dependent PARP1 activation while PARP1 has been reported
to be a target of AMPkα [61]. During proinflammatory situ-
ations, PARP1 is able to modulate the expression of Bcl-6
through its binding at Bcl-6 intron 1. Phosphorylation of
PARP1 at serine 177 (Ser-177) by AMPk kinase promotes
dissociation from Bcl-6 intron 1, increases Bcl-6 expression,
and inhibits expression of inflammatory mediators, demon-
strating an anti-inflammatory crosstalk linking AMPk and
PARP1 activity [61].
To evaluate the possibility of a mutual interaction
between AMPkα and PARP1 leading to PARP1 phosphory-
lation, starved cells treated with the AMPk kinase inhibitor
compound C showed decreased PARylation of AMPkα,
suggesting that full AMPk activity was needed for PARP1
activation during nutrient deprivation [59]. (II) Starvation
in a PARP1 inhibition context: PARP1-deficient cells display
a reduced production of ROS, even at very early time points
following starvation [58]. This finding is consistent with
previous results showing reduced ROS production in lym-
phocytes challenged with exogenous oxidative stress and
treated with PARP inhibitors [62]. PARP1 knockout cells
or cells treated with a PARP inhibitor show sharply reduced
DNA damage levels, and the machinery to repair DNA dam-
age is not as efficient as in PARP1 wild-type cells, resulting in
a residual level of damage after long times of starvation of
which the final consequence is compromised autophagy
and prominent apoptosis cell death [58].
In PARP1-inactivated cells, the absence of efficient
PARylation retains the stability of the PARP1/AMPkα
complex and AMPkα is not transported from the nucleus
to the cytosol during starvation. The final consequence is
an inefficient activation of the cytosolic AMPkα pool, par-
tially maintaining the activity of mTORC1 and seriously
compromising the activation of ULK1 and the initiation of
phagophores [59] (see Figure 3(b)).
The crucial role of neonatal autophagy was clearly dem-
onstrated by targeted inactivation of the autophagy-related
genes ATG5 and ATG7. Mice deficient in ATG5/ATG7 were
apparently normal in birth, except for a slightly lower body
weight than control or wild-type (approximately 10% in
ATG5-null and 18% in ATG7-null mice). Moreover,
ATG7-null animals presented deficiency in the liver causing
hepatomegaly and hepatic cell swelling. The curve of survival
of neonates demontrated that the null animals showed seri-
ous difficulties to growth and survive, indicating the impor-
tant role of the proteins that regulate the formation of
autophagosomes during embryonic development [63]. It is
described that phenotypically, PARP1 knockout mice had
the average litter size smaller than wild-type mice (approxi-
mately 20%). Several in vivo observations in starved neonates
of PARP1 mutant mice showed decreased frequency of
hepatic multimembrane lipid droplets, presumably autopha-
gosomes engulfing mitochondria and cytosol portions,
implying a physiological role of PARP1 in starvation-
induced autophagy [58].
In conclusion, the nucleus and the functional interaction
between PARP1 and AMPkα are initial and essential sensors
of the metabolic alterations derived from perturbations in the
nutritional extracellular status, not necessarily related with
the alterations in genomic integrity.
9. Concluding Remarks
One of the most remarkable findings in our study is the need
for the AMPkα nuclear export to perform its cytosolic func-
tion during the initial steps of starvation-induced autophagy,
but how PARylated AMPkα coming out of the nucleus “hits”
cytosolic AMPkα remains to be clarified. Nuclear sensors,
including PARP1, detect perturbations in nuclear and genetic
homeostasis to activate a mechanism to repair and, in case of
failure, promote different types of cell death for the benefit of
the organism homeostasis. Considering different studies, we
could conclude that DNA lesions are potential activators of
nonselective autophagy mechanisms. In this way, we have
enough evidence to affirm that PARP1 and PARylation play
a key role in autophagy, beyond the nuclear activation of
PARP1.
This model has been demonstrated in normal and cancer
cells, so efficient treatment with drugs on cancer cells opens
a new, interesting, and novel field with PARP inhibitors
and molecules targeting prosurvival pathways under physi-
ological stimuli such as starvation, hypoxia, growth factor
deprivation, etcetera.
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